Furthermore, given that a wide variety of cancers are known to express MerTK, including nearly 80-90% of AML patient samples (17), MerTK inhibitors could potentially have a dual cell intrinsic effect on AML cells and antitumor immune response through LAMs. This evidence concerns the gene MERTK and acute myeloid leukemia.